An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

AIMS/HYPOTHESIS: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in individuals with type 2 diabetes and hypertension. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetologia
Main Authors: Hanrahan, John P., Seferovic, Jelena P., Wakefield, James D., Wilson, Phebe J., Chickering, Jennifer G., Jung, Joon, Carlson, Kenneth E., Zimmer, Daniel P., Frelinger, Andrew L., Michelson, Alan D., Morrow, Linda, Hall, Michael, Currie, Mark G., Milne, G. Todd, Profy, Albert T.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054374/
https://ncbi.nlm.nih.gov/pubmed/31858186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-019-05062-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados